Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
1.35
Nov 13 • 3:59 PM ET Dollar change-0.19 Percentage change(-12.66%)
Aftermarket Close
1.37
Aftermarket • 7:56 PM ET Dollar change+0.02 Percentage change(1.86%)
Index
-
Market Cap
10.17M
Enterprise Value
11.17M
Income
-10.26M
Sales
3.31M
Book/sh
0.49
Cash/sh
0.26
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
32
IPO
Feb 13, 2014
P/E
-
Forward P/E
-
PEG
-
P/S
3.07
P/B
2.73
P/C
5.08
P/FCF
-
EV/EBITDA
-
EV/Sales
3.37
Quick Ratio
0.99
Current Ratio
1.84
Debt/Eq
0.88
LT Debt/Eq
0.74
Option/Short
No / Yes
EPS (ttm)
-2.25
EPS next Y
-1.06
EPS next Q
-0.34
EPS this Y
70.78%
EPS next Y
40.93%
EPS next 5Y
54.77%
EPS past 3/5Y
92.03% 80.47%
Sales past 3/5Y
-13.28% 11.38%
EPS Y/Y TTM
67.55%
Sales Y/Y TTM
160.79%
EPS Q/Q
93.09%
Sales Q/Q
952.88%
Insider Own
19.80%
Insider Trans
0.00%
Inst Own
12.75%
Inst Trans
14.52%
ROA
-92.14%
ROE
-250.39%
ROIC
-158.28%
Gross Margin
54.71%
Oper. Margin
-303.38%
Profit Margin
-309.87%
SMA20
-17.67%
SMA50
-25.36%
SMA200
-36.98%
Trades
Shs Outstand
6.89M
Shs Float
6.06M
52W High
4.46 -69.84%
52W Low
1.40 -3.93%
Volatility
12.22% 7.96%
ATR (14)
0.14
RSI (14)
28.38
Beta
0.57
Rel Volume
1.46
Avg Volume
53.01K
Volume
77,627
Perf Week
-13.78%
Perf Month
-24.01%
Perf Quarter
-17.99%
Perf Half Y
-40.62%
Perf YTD
-65.16%
Perf Year
-56.05%
Perf 3Y
-98.64%
Perf 5Y
-99.99%
Perf 10Y
-100.00%
Prev Close
1.54
Price
1.35
Change %
-12.66%
Consensus
Strong Buy
Avg. Price Target
$9.25
Implied Upside
+587.7%
Analysts2incl. previous ratings
Rating Distribution2 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Apr 13, 2026Initiated
HH.C. Wainwright
Buy$10+643.5%
Sep 12, 2019Initiated
AAscendiant Capital Markets
Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lyons Christopher MichaelDirectorMar 02 '26Buy2.907,53421,8498,292Mar 10 09:00 AM
Lyons Christopher MichaelDirectorFeb 25 '26Buy2.967582,244758Mar 10 09:00 AM
MOYES JAY MDirectorFeb 23 '26Buy2.911,0002,9104,000Feb 25 09:00 AM
Anderson Mark LewisDirectorFeb 18 '26Buy3.023,0009,06018,000Feb 19 09:00 AM
Honigblum Gregg R.Chief Investment OfficerDec 08 '25Buy4.268,20034,896201,067Dec 09 08:00 AM
Honigblum Gregg R.Chief Investment OfficerDec 05 '25Buy3.9365,000255,350139,000Dec 08 08:00 AM
SINTX Technologies, Inc. is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY technology platform being developed for biocomposite and 3D printing applications. The company was founded by Aaron A. Hofmann and Ashok C. Khandkar in December 1996 and is headquartered in Salt Lake City, UT.
CEO & Chairman of the BoardMr. Eric K. Olson
Chief Financial OfficerMr. Kevin Trask
Chief Investment Officer & DirectorMr. Gregg Richard Honigblum
PresidentMr. Ryan Elmore
Chief Legal OfficerMr. Kevin J. Ontiveros Esq.